Glycyrrhizin alleviates the toxicity of hydroxychloroquine in treating oral lichen planus by occupying heat shock protein 90 alpha

作者：Houshang Wang, Jingjing Luo, Kunmeng Luo, Lanyan Wu, Tao Hu, Jin Yang, Hongmei Zhou · 发表于：Phytomedicine · 年份：2024 · DOI：10.1016/j.phymed.2024.156059 · 被引用次数：5 · 研究领域：Oral Health Pathology and Treatment、Pharmacological Effects of Natural Compounds、Salivary Gland Disorders and Functions

• A randomized and positive-controlled trial is the first to investigate the efficacy of hydroxychloroquine for erosive oral lichen planus characterized by extensive quantized erosions. • We firstly demonstrated that phytomedicine glycyrrhizin holds promise for detoxifying hydroxychloroquine in treating oral lichen planus by occupying the HSP90α binding site, providing a theoretical basis for precise phytopreparations combined with conventional/official medicine therapy. • As theoretically and experimentally evidenced, hydroxychloroquine and glycyrrhizin can exert therapeutic effects on oral lichen planus by innovatively acting as an agonist for HSP90α/β. Oral lichen planus (OLP) is a common chronic inflammatory disease with the potential of malignant transformation. Hydroxychloroquine (HCQ), derived from quinine originating from Cinchona spp. bark, is a commonly prescribed off-label for OLP. However, it lacks robust evidence-based medicine practice, as well as theoretical guidance for its pharmacodynamic targets and for mitigating adverse reactions. To compare the efficacy of HCQ with first-line treatment prednisone for treating severe erosive OLP and to identify compatible phytomedicine that is reasonably available based on elucidating the molecular targets related to clinical benefits and adverse reactions. We performed a single-center, randomized, investigator-blinded, positive-controlled, non-inferiority trial. Patients who met the enrollment criteria were randomly alloc...